Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Immune oncology in breast cancer: KEYNOTE-086, NCI 10013, & AIPAC

Sangeetha Reddy, MD, UT Southwestern Medical Center, Dallas, TX, discusses the latest updates in immune-oncology as presented at this year’s virtual San Antonio Breast Cancer Symposium (2020). Dr Reddy summarises three abstracts, relating to the KEYNOTE-086 study (NCT02447003) evaluating pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer, a National Cancer Institute (NCI) study evaluating carboplatin and paclitaxel with or without atezolizumab before surgery in patients with newly diagnosed triple-negative breast cancer, and finally, the AIPAC randomized Phase IIb study (NCT02614833) evaluating the efficacy of eftilagimod alfa (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor-positive metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.